The JAK Inhibitor Shift in Vitiligo: A Critical Review of Clinical Data and Economic Realities
EP. 1: Vitiligo Types, Progression, and What Patients Fear Most
ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a patient needs urgent intervention or watchful monitoring.
EP. 2: Why Body Surface Area Alone Doesn't Capture Vitiligo Severity
ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD Body surface area offers a simple starting point for gauging vitiligo severity, but the panel argues that phenotype markers, anatomic location, and disease activity carry more weight in shaping treatment urgency than surface area alone.
